Comparative Pharmacology
Head-to-head clinical analysis: GILDESS FE 1 20 versus MIUDELLA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: GILDESS FE 1 20 versus MIUDELLA.
GILDESS FE 1/20 vs MIUDELLA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination oral contraceptive: ethinyl estradiol suppresses gonadotropin release; norethindrone induces progestational changes in endometrium and cervical mucus, preventing ovulation and fertilization.
MIUDELLA (everolimus) is an mTOR inhibitor that binds to the FKBP-12 protein to form a complex that inhibits the mTOR kinase activity, thereby reducing cell proliferation, angiogenesis, and glucose uptake.
One tablet orally once daily for 21 days followed by 7 placebo tablets per 28-day cycle.
Intravenous: 1.5 mg/kg every 12 hours for 14 days.
None Documented
None Documented
Ethinyl estradiol: terminal half-life approximately 13 hours (range 10-15 h). Desogestrel: metabolized to etonogestrel; etonogestrel terminal half-life about 28 hours (range 20-40 h). Clinical context: steady-state reached within 7-10 days.
Terminal elimination half-life is 18-24 hours in healthy adults; prolonged in renal impairment (up to 40 hours in severe cases).
Approximately 60-65% renal (as metabolites), 30-35% fecal (as metabolites and unchanged drug). Ethinyl estradiol and desogestrel metabolites are excreted primarily via urine and feces. Etonogestrel (active metabolite) is excreted mainly via feces (40%) and urine (32%).
Primarily renal excretion of unchanged drug (85-90%); biliary/fecal elimination accounts for 5-10%.
Category C
Category C
Oral Contraceptive
Oral Contraceptive